BioClavis is a UK-based personalized diagnostics spin-out of US based BioSpyder Technologies. We’re enabling the full promise and clinical utility of “omic” testing and to deliver cost-effective care for individual patients in coordination with and in the context of the practical realities in today’s evolving and expanding healthcare systems. BioClavis leverages the proprietary TempOSeq® transcriptomic/genomic platform technology (developed by BioSpyder) for efficiently analyzing large cohorts with customizable biomarker panels of tens to thousands of genes simultaneously, quickly and efficiently. It has critical usability features, controls, and does not require specialized instrumentation, making it ideal for expansion into the clinic. These strengths--in concert with centralized patient samples, clinical research partners, and economic decision making in the UK--allow accelerated content discovery, product development and adoption of a new generation of cost-disruptive precision medicine testing worldwide.